Evidence map›Paper›PMID 24498551›Full record

ReviewOncoimmunology2013

Vaccine therapy for pancreatic cancer.

Bulent Salman, Donger Zhou, Elizabeth M Jaffee, Barish H Edil, Lei Zheng

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Focus on Pancreatic Cancer Microenvironment.Current oncology (Toronto, Ont.) · 2024
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Immune defects in pancreatic cancer.Annals of pancreatic cancer · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Bulent SalmanDepartment of Surgery; Johns Hopkins University of School of Medicine; Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Research Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA.
Donger ZhouDepartment of Oncology; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA.
Elizabeth M JaffeeDepartment of Oncology; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Skip Viragh Pancreatic Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Research Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA.
Barish H EdilDepartment of Surgery; University of Colorado; Aurora, CO USA.
Lei ZhengDepartment of Surgery; Johns Hopkins University of School of Medicine; Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Research Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA ; Department of Oncology; Johns Hopkins University School of Medicine; Baltimore, MD USA ; The Skip Viragh Pancreatic Cancer Center; Johns Hopkins University School of Medicine; Baltimore, MD USA.
Johns Hopkins Medicine · USCancer Research Center · USJohns Hopkins University · USUniversity of Colorado Denver · US

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6M
Dissecting the mechanisms of immune tolerance within the pancreatic tumor's microK23CA148964 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHENG, LEI · 2010 to 2014
$888k
NCI NIH HHS K23 CA148964NCI NIH HHS P50 CA062924
6 · The paper itself

Abstract

Pancreatic cancer is a lethal disease and currently available therapies have significant limitations. Pancreatic cancer is thus an ideal setting for the development of novel treatment modalities such as immunotherapy. However, relevant obstacles must be overcome for immunotherapeutic regimens against pancreatic cancer to be successful. Vaccine therapy relies on the administration of biological preparations that include an antigen that (at least ideally) is specifically expressed by malignant cells, boosting the natural ability of the immune system to react against neoplastic cells. There are a number of ways to deliver anticancer vaccines. Potent vaccines stimulate antigen presentation by dendritic cells, hence driving the expansion of antigen-specific effector and memory T cells. Unlike vaccines given as a prophylaxis against infectious diseases, anticancer vaccines require the concurrent administration of agents that interfere with the natural predisposition of tumors to drive immunosuppression. The safety and efficacy of vaccines against pancreatic cancer are nowadays being tested in early phase clinical trials.

Indexed as

cancer vaccineclinical trialsimmune checkpointimmunotherapypancreatic cancer

Identifiers

PMID24498551
PMCPMC3912009
OpenAlexW2019264711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.